Scholarlink

<p>This study aimed to assess the prognostic value of the THRIVE scale in patients aged ≥ 60 years with acute ischemic stroke (AIS) after intravenous thrombolysis with the non-immunogenic staphylokinase compared with alteplase. The post-hoc analysis of FRIDA trial results was performed and enrolled patients aged ≥ 60 years were divided into two groups in accordance with the modified Rankin scale (mRS) score on day 90: good-outcome (mRS 0–2) and poor-outcome (mRS 3–6) groups. The receiver operating characteristic (ROC) curves were compared using Delong test. For all-cause mortality on day 90 the predicted AUC value by the THRIVE scale was 0.8 (0.71–0.9) in the non-immunogenic staphylokinase group and 0.76 (0.66–0.87) in the alteplase group (<i>p</i> = 0.57). For poor outcome, AUC value was 0.73 (0.64–0.82) in the non-immunogenic staphylokinase group and 0.79 (0.71–0.87) in alteplase group (<i>p</i> = 0.36). Thus, our study confirmed the prognostic value of the THRIVE scale to predict the outcomes of the patients aged ≥ 60 years treated with the non-immunogenic staphylokinase.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale

  • 期刊论文

  • 发表日期：

    2025年11月16日

查看全文
  • Nikolay A. Shamalov,
  • Zhanna Yu. Chefranova,
  • Elena B. Yarovaya,
  • Vladimir A. Kutsenko,
  • Natalya A. Marskaya,
  • Andrey M. Semenov,
  • Mikhail P. Semenov,
  • Sergey V. Ivanov,
  • Yulia A. Romashova,
  • Sergey S. Markin

摘要

This study aimed to assess the prognostic value of the THRIVE scale in patients aged ≥ 60 years with acute ischemic stroke (AIS) after intravenous thrombolysis with the non-immunogenic staphylokinase compared with alteplase. The post-hoc analysis of FRIDA trial results was performed and enrolled patients aged ≥ 60 years were divided into two groups in accordance with the modified Rankin scale (mRS) score on day 90: good-outcome (mRS 0–2) and poor-outcome (mRS 3–6) groups. The receiver operating characteristic (ROC) curves were compared using Delong test. For all-cause mortality on day 90 the predicted AUC value by the THRIVE scale was 0.8 (0.71–0.9) in the non-immunogenic staphylokinase group and 0.76 (0.66–0.87) in the alteplase group (p = 0.57). For poor outcome, AUC value was 0.73 (0.64–0.82) in the non-immunogenic staphylokinase group and 0.79 (0.71–0.87) in alteplase group (p = 0.36). Thus, our study confirmed the prognostic value of the THRIVE scale to predict the outcomes of the patients aged ≥ 60 years treated with the non-immunogenic staphylokinase.

Graphical abstract